

DAFTAR PUSTAKA

- Anaya, Juan-Manuel. Shoenfeld, Yehuda, Buttgerit, Frank. A. Gonzalez-Gay, Miguel. (2014). Autoimmune Rheumatic Diseases. *BioMed Research International*, vol. 2014, Article ID 952159, 3 pages. <https://doi.org/10.1155/2014/952159>
- Arleo T, Tong D, Shabto J, O'Keefe G, Khosroshahi A. Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population. *Clin Rheumatol*. (2021) 40:2633– 42. doi: 10.1007/s10067-021-05578-x
- Brito-Zerón P, Melchor S, Seror R, Priori R, Solans R, Kostov B, et al. SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. *Rheumatology*. (2020) 60:2946– 57. doi: 10.1093/rheumatology/keaa748
- Belen-Apak, F. B., & Sarıalioğlu, F. (2020). Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. *Journal of thrombosis and thrombolysis*, 50(2), 278-280.
- Biswas, I., & Khan, G. A. (2020). Coagulation disorders in COVID-19: role of toll-like receptors. *Journal of Inflammation Research*, 13, 823.
- Biswas PS, Sen D, Homchoudhary A, Makkar D, Kapoor M, Goyal A. Association of demographic, clinical, laboratory, and radiological characteristics with outcomes of COVID-19 patients: A systematic review and Meta-analysis. *J Microbiol Infect Dis*. 2019;9(3):121–35
- Borghesi A, Maroldi R. (2020). COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. *La Radiologia Medica* 125:509–513
- Cascella M, Rajnik M, Aleem A. (2022). Features, Evaluation, and Treatment of Coronavirus (COVID-19). *Stat Pearls Publishing*; Dilansir dari: <https://www.ncbi.nlm.nih.gov/>
- Charles, P. G., Wolfe, R., Whitby, M., Fine, M. J., Fuller, A. J., Stirling, R., Wright, A. et al. (2008). SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 47(3), 375–384. <https://doi.org/10.1086/589754>
- Chung RYK, Li MM (2020) Anti-Chinese sentiment during the 2019-nCoV outbreak. *Lancet* 395(10225):686–687
- Cordtz R, Lindhardtsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. *Rheumatology*. (2020). doi: 10.1093/rheumatology/keaa897. [Epub ahead of print].

- Dahlan, Sopiudin M. 2013. Statistik Untuk Kedokteran dan Kesehatan: Deskriptif, Bivariat, dan Multivariat Dilengkapi Aplikasi dengan menggunakan SPSS. Jakarta: Salemba Medika
- Dalpe AH, Helm M. RNA mediated Toll-like receptor stimulation in health and disease. *RNA Biol.* 2012;9(6):828–842. doi:10.4161/rna.2020644
- Deane, K. D., & El-Gabalawy, H. (2014). Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. *Nature reviews. Rheumatology*, 10(4), 212–228.
- D'Silva KM, Serling-Boyd N, Wallwork R. (2020). Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US hot spot. *Ann. Rheum. Dis.* 79;1156–1162. doi: 10.1136/annrheumdis-2020-217888.
- Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention (2020). *Zhonghua liuxingbingxue zazhi*, 41(2), 145–151. <https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003>
- Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B, Gu X, Wang Y, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Wu W, Cao B. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. *Eur Respir J.*(2020) 10;56(3):2002113. doi: 10.1183/13993003.02113-2020.
- Francesconi, P., Cantini, F., Profili, F., Mannoni, A., Bellini, B., & Benucci, M. (2021). COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study. *Joint bone spine*, 88(3), 105131. <https://doi.org/10.1016/j.jbspin.2021.105131>
- Fernandez-Ruiz, R., Paredes, J. L., & Niewold, T. B. (2021). COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. *Translational research: the journal of laboratory and clinical medicine*, 232, 13–36.
- Fuad, M., Oehadian, A., Prihatni, D., & Marthoenis, M. (2021). Neutrophil-to-lymphocyte ratio and Covid-19 symptom-based severity at admission. *Althea Medical Journal*, 8(1), 1-6.
- Fox, S. E., Akmatbekov, A., Harbert, J. L., Li, G., Quincy Brown, J., & Vander Heide, R. S. (2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *The Lancet. Respiratory medicine*, 8 (7), 681–686. [https://doi.org/10.1016/S2213-2600\(20\)30243-5](https://doi.org/10.1016/S2213-2600(20)30243-5).
- Gianfrancesco M, Hyrich KL, Al-Adely S. (2020). Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann. Rheum. Dis.*:1-8. doi: 10.1136/annrheumdis-2020-217871.
- Grainger, R., Machado, P. M., & Robinson, P. C. (2021). Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. *Best practice & research. Clinical rheumatology*, 35(1), 101657.

- Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L. Characteristics associated with hospitalisation for COVID- 19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. *Rheumatol Int.* (2020) 79:859–66. doi: 10.1136/annrheumdis-2020-217871
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032
- Goldblatt, F., & O'Neill, S. G. (2013). Clinical aspects of autoimmune rheumatic diseases. *Lancet.* 382(9894), 797–808. [https://doi.org/10.1016/S0140-6736\(13\)61499-3](https://doi.org/10.1016/S0140-6736(13)61499-3)
- Grange, L., Guilpain, P., Truchetet, M. E., Cracowski, J. L., & French Society of Pharmacology and Therapeutics (2020). Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. *Therapie*, 75(4), 335–342. <https://doi.org/10.1016/j.therap.2020.06.013>
- Hidayat, Rudi. Isbagio, Harry. Ariane, Anna., et al. (2020). Characteristics of Patients with Autoimmune Rheumatic Disease in the Era of COVID-19 Pandemic in Indonesia. *Indonesian Journal of Rheumatology* Vol 12 Issue 1 2020
- Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. *Arthritis Rheumatol.* (2020) 72:1981–9. doi: 10.1002/art.41456
- JiW, HuhK, KangM, HongJ, BaeGH, LeeR, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. *J Korean Med Sci.* (2020) 35:e237. doi: 10.3346/jkms.2020.35.e237
- Huang, Y., Yang, C., Xu, X. F., Xu, W., & Liu, S. W. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacologica Sinica*, 41(9), 1141–1149.
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *cell*, 181(2), 271–280.
- Imran MM, Ahmed U, Usman U, Ali M, Shaukat A, Gul N. (2021) Neutrophil/lymphocyte ratio – A marker of COVID-19 pneumonia severity. *Int J Clin Pract.*; 2021: e13698.
- Jithin Mathew, Siddharth Jain, Terence Susngi, Shankar Naidu, Varun Dhir, Aman Sharma, Sanjay Jain, Shefali Khanna Sharma. Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study, *Rheumatology Advances in Practice*, 2023: Volume 7, Issue 1, , rkad025.

- Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J, Wani F, Kumar A, Vallabhaneni S, Khan MZ. COVID-19 and Hypercoagulability: A Review. *Clin Appl Thromb Hemost*. 2020 Jan – Dec ; 26
- Lazar Neto F, Marino LO, Torres A, Cilloniz C, Meirelles Marchini JF, Garcia de Alencar JC, Palomeque A, Albacar N, Brandão Neto RA, Souza HP, Ranzani OT; COVID Registry Team; Medical Students; Residents; Attending physicians. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. *Clin Microbiol Infect*. 2021 Jul;27(7):1037.e1-1037.e8. doi: 10.1016/j.cmi.2021.03.002. Epub 2021 Apr 2. PMID: 33813111; PMCID: PMC8016546
- Lian J, Jin C, Hao S, Zhang X, Yang M, Jin X, *et al*. High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: A multicenter retrospective study. *Aging* (Albany NY). 2020;12(14):13849–59.
- Mezalek, Z. T., Khibri, H., Ammouri, W., Bouaouad, M., Haidour, S., Harmouche, H., ... & Adnaoui, M. (2020). COVID-19 associated coagulopathy and thrombotic complications. *Clinical and Applied Thrombosis/Hemostasis*, 26, 1076029620948137.
- Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., *et al*. (2007). Infectious Diseases Society of America, & American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 44 Suppl 2(Suppl 2), S27–S72. <https://doi.org/10.1086/511159>
- Marti, C., Garin, N., Grosgrin, O., Poncet, A., Combescure, C., Carballo, S., & Perrier, A. (2012). Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. *Critical care (London, England)*, 16(4), R141. <https://doi.org/10.1186/cc11447>
- Moutsopoulos H. M. (2021). Autoimmune rheumatic diseases: One or many diseases? *Journal of translational autoimmunity*, 4, 100129. <https://doi.org/10.1016/j.jtauto.2021.100129>
- Murphy, G., Lisnevskaja, L., & Isenberg, D. (2013). Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. *Lancet* (London, England), 382(9894), 809–818. [https://doi.org/10.1016/S0140-6736\(13\)60889-2](https://doi.org/10.1016/S0140-6736(13)60889-2)
- Moradi EV, Teimouri A, Rezaee R, Morovatdar N, Foroughian M, Layegh P, *et al*. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. *Am J Emerg Med*. 2021; 40:11-14.
- Ng M-Y, Lee EY, Yang J *et al* (2020) Imaging profile of the COVID-19 infection: radiologic findings and literature review. *Radiol Cardiothoracic Imaging* 2:1
- Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, *et al*. Clinical course, severity and mortality in a cohort of patients

- with COVID-19 with rheumatic diseases. *Ann Rheum Dis.* (2020) 79:1659– 61. doi: 10.1136/annrheumdis-2020-218054
- Osuchowski, M. F., Winkler, M. S., Skirecki, T., Cajander, S., Shankar-Hari, M., Lachmann, G., & Rubio, I. (2021). The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. *The Lancet Respiratory Medicine*, 9(6), 622-642.
- Pakpahan, F. S., Bihar, S. ., Syarani, F. ., & Eyanoer, P. C. . (2021). Accuracy Between CURB-65 Score and PSI in Determining The Prognosis of Community-Acquired Pneumonia Patients at H. Adam Malik General Hospital, Medan. *Respiratory Science*, 1(3), 174-181. <https://doi.org/10.36497/respirsci.v1i3.25>
- Parasher, A. (2021). COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. *Postgraduate medical journal*, 97(1147), 312-320.
- Pablos, J. L., Abasolo, L., Alvaro-Gracia, J. M., Blanco, F. J., Blanco, R., Castrejón, I., Fernandez-Fernandez, D., *et al.* (2020). Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. *Annals of the rheumatic diseases*, 79(9), 1170–1173.
- Pablos JL. Clinical outcomes of hospitalised patients with COVID- 19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. *Cells.* (2020) 79:1544–9. doi: 10.1136/annrheumdis-2020-21829
- Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. *Chest.* (2020) 158:1397–408. doi: 10.1016/j.chest.2020.06.006
- Peach, E., Rutter, M., Lanyon, P., Grainge, M. J., Hubbard, R., Aston, J., Bythell, M., Stevens, S., & Pearce, F. (2021). Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic. *Rheumatology (Oxford, England)*, 60(4), 1902–1909.
- Putra, Oki N., Anggraini, MA., Hardiyono H. (2021). Efek Obat Imunosupresan Pada Pasien Autoimun dengan COVID-19 (A Scoping Review of The Clinical Evidence). *J Islamic Pharm.* Vol 6, No 2
- Rizo-Téllez SA, Méndez-García LA, Flores- Rebollo C, Alba-Flores F, Alcántara-Suárez R, Manjarrez-Reyna AN, *et al.* The neutrophil-to-monocyte ratio and lymphocyte-to-neutrophil ratio at admission predict in-hospital mortality in mexican patients with severe sars-cov-2 infection (Covid-19). *Microorganisms.* 2020;8(10):1560
- Robinson, P. C., & Yazdany, J. (2020). The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. *Nature reviews. Rheumatology*, 16(6), 293–294.
- Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A & Wilson, W. H. (2020). Inhibition of Bruton tyrosine

- kinase in patients with severe COVID-19. *Science immunology*, 5(48), eabd0110.
- Restrepo Marcos I., Anzueto, Antonio. (2009) Severe Community-Acquired Pneumonia. *Infectious Disease Clinics of North America*, Volume 23, Issue 3, 503-520, <https://doi.org/10.1016/j.idc.2009.04.003>.
- Restrepo, M. I., Mortensen, E. M., Rello, J., Brody, J., & Anzueto, A. (2010). Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. *Chest*, 137(3), 552–557.
- Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Peach E, Bythell M, Stilwell P, Aston J, Stevens S, Pearce FA. COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: results from the RECORDER project. *Rheumatology (Oxford)*. 2022 Aug 3;61(8):3161-3171. doi: 10.1093/rheumatology/keab794. PMID: 34698821; PMCID: PMC8586729.
- Rongrong Pang, Jun Zhao, Zhenhua Gan, Zhiliang Hu, Xiang Xue, Yangjun Wu, et al. Evolution of COVID-19 in patients with autoimmune rheumatic diseases. *Aging*. (2020) 12:9. doi: 10.18632/aging.202193
- Sarzi-Putteni P, Marotto D, Caporali R, Montecucco CM, Favalli EG, Franceschini F, et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: a multicentre retrospective study. *J Autoimmun*. (2021) 116:102545. doi: 10.1016/j.jaut.2020.102545
- Saglietto, A., D'Ascenzo, F., Zoccai, G. B., & De Ferrari, G. M. (2020). COVID-19 in Europe: The Italian lesson. *Lancet* (London, England), 395(10230), 1110–1111.
- Santos CS, Morales CM, Álvarez ED. (2020). Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. *Clin. Rheumatol*. 39:2789–2796, 2020, doi: 10.1007/s10067-020-05301-2.
- Shoenfeld, Y., Gerli, R., Doria, A., Matsuura, E., Cerinic, M. M., Ronda, N., Jara, L. J., Abu-Shakra, M., Meroni, P. L., & Sherer, Y. (2005). Accelerated atherosclerosis in autoimmune rheumatic diseases. *Circulation*, 112 (21), 3337–3347.
- Shin, Y. H., Shin, J. I., Moon, S. Y., Jin, H. Y., Kim, S. Y., et al. (2021). Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. *The Lancet. Rheumatology*, 3(10), e698–e706.
- Van der Heijde D, Daikh DI, Betteridge N, et al. (2018) Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). *Ann Rheum Dis*. 77:829-832.
- Valley, T. S., Sjoding, M. W., Ryan, A. M., Iwashyna, T. J., & Cooke, C. R. (2015). Association of Intensive Care Unit Admission with Mortality Among Older Patients with Pneumonia. *JAMA*, 314(12), 1272–1279.

- Valley, T. S., Sjoding, M. W., Ryan, A. M., Iwashyna, T. J., & Cooke, C. R. (2015). Association of Intensive Care Unit Admission With Mortality Among Older Patients With Pneumonia. *JAMA*, 314(12), 1272–1279.
- Vázquez-Díaz M, Freites Nuñez DD, Leon L. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. *Rheumatol Int.* (2020) 79:1393–9. doi: 10.1136/annrheumdis-2020-217984
- Wang, W., Tang, J., & Wei, F. (2020). Updated understanding of the outbreak of 2019 novel coronavirus (2019- nCoV) in Wuhan, China. *Journal of medical virology*, 92(4), 441-447.
- Wahren-Herlenius, M., & Dörner, T. (2013). Immunopathogenic mechanisms of systemic autoimmune disease. *Lancet* (London, England), 382 (9894), 819–831. [https://doi.org/10.1016/S0140-6736\(13\)60954-X](https://doi.org/10.1016/S0140-6736(13)60954-X)
- Wang, Lifeng; Wang, Fu-Sheng; Gershwin, M. Eric (2015). Human autoimmune diseases: a comprehensive update. *Journal of Internal Medicine*, 278(4), 369–395. doi:10.1111/joim.12395
- Wei, P. F. (2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). *Chinese medical journal*, 133(9), 1087-1095.
- Wong HYF, Lam HYS, Fong AH-T *et al* Frequency and distribution of chest radiographic findings in COVID-19 positive patients. *Radiology Published Online: Mar -27- 2022*
- World Health Organization (WHO). (2021). WHO Coronavirus (COVID-19) Dashboard. Diakses pada tanggal 8 November 2021 pada halaman website <https://covid19.who.int/>
- Xu J, Xu C, Zhang R, Wu M, Pan C, Li X, *et al*. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. *Sci Rep.* 2020;10(1):15058
- Yang, A. P., Liu, J. P., Tao, W. Q., & Li, H. M. (2020). The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *International immunopharmacology*, 84, 106504. <https://doi.org/10.1016/j.intimp.2020.106504>
- Yasin, R., & Gouda, W. (2020). Chest X-ray findings monitoring COVID-19 disease course and severity. *Egyptian Journal of Radiology and Nuclear Medicine*, 51(1), 1-18.
- Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. *Clinical immunology*, 215, 108427. Biswas I, Khan GA. Coagulation Disorders in COVID-19: Role of Toll-like Receptors. *J Inflamm Res.* 2020 Oct 29; 13: 823 -828. doi: 10.2147/JIR. S271768. PMID: 33149655; PMCID: PMC7605922
- Ye C, Cai Z, Shen G. (2020). Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. *Ann. Rheum. Dis.* 79:1007–1013.
- Zhong, J., Shen, G., Yang, H., Huang, A., Chen, X., Dong, L., Wu, B., Zhang, A., Su, L., Hou, X., Song, S., Li, H., Zhou, W., Zhou, T., Huang, Q., Chu, A., Braunstein, Z., Rao, X., Ye, C., & Dong, L. (2020). COVID-19 in patients with rheumatic disease in Hubei province, China: a